基于环素A的PROTACs可以消耗大量的细胞环素A,而不会抑制T细胞激活
Katharina Hilbig1, Russell Towers2, Marc Schmitz3,4
1B CUBE Center for Molecular Bioengineering, Technische Universität Dresden, Tatzberg 41, 01307 Dresden, Germany.
Molecules (Basel, Switzerland)
|June 27, 2024
概括
研究人员开发了PROTACs来降解环素A (CypA),这是一个大量的蛋白质,与疾病有关. 基于CsA的PROTAC在免疫细胞中耗尽了CypA而不会影响其功能,显示出治疗潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 环林A (CypA) 是一种细胞质蛋白质,与癌症扩散和HIV-1等病毒感染有关.
- 环素A (CsA) 与CypA结合,但其免疫抑制作用源于氨酸抑制,而不是直接与CypA结合.
- 针对像CypA这样丰富的蛋白质对治疗干预提出了挑战.
研究的目的:
- 设计蛋白质溶解向嵌合体 (PROTACs),以诱导CypA的细胞内降解.
- 在免疫细胞中研究针对CypA的PROTACs的疗效.
- 为了确定CypA降解是否可以在不损害免疫细胞功能的情况下实现.
主要方法:
- 设计和合成PROTAC化合物,将E3酶连接物连接到CypA结合剂 (基于和基于CsA).
- 在纳米分子度下评估PROTAC诱导的HeLa,纤维细胞和淋巴细胞细胞系中的CypA降解.
- 在用基于CSA的PROTAC治疗后,评估免疫细胞的增殖和细胞因子的产生.
主要成果:
- 基于和基于CsA的PROTAC在nM度下,在各种细胞类型中有效降解CypA.
- 一种基于CsA的PROTAC (P3) 在淋巴细胞中有效地消耗了CypA.
- P3治疗没有影响淋巴细胞增殖或细胞因子的产生,这表明免疫细胞功能得到保护.
结论:
- 在低药物度下,PROTAC技术可用于耗尽丰富的蛋白质CypA.
- 使用PROTACs的向CypA降解可以在免疫细胞中实现,而不会对其激活产生不良影响.
- 这种方法为探索在疾病背景下调节CypA水平的治疗潜力开辟了道路.
更多相关视频
相关概念视频
Cytotoxic T Cells-mediated Immune Response
888
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
888
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K


